Bakker Noor A M, de Boer Renate, Marie Corinne, Scherman Daniel, Haanen John B A G, Beijnen Jos H, Nuijen Bastiaan, van den Berg Joost H
Divisions of Immunology, Pharmacy & Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanslaan 121, 1066 CX, Amsterdam, the Netherlands; Amsterdam Biotherapeutics Unit, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands.
CNRS, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), UMR 8258, F-75006, Paris, France; INSERM, UTCBS U 1022, F-75006, Paris, France; Université Paris Descartes, Sorbonne-Paris-Cité, UTCBS, F-75006, Paris, France; Chimie ParisTech, PSL Research University, UTCBS, F-75005, Paris, France.
J Biotechnol. 2019;306S:100007. doi: 10.1016/j.btecx.2019.100007. Epub 2019 May 11.
In the past years, the demand for small batches of clinical grade plasmid DNA has been growing. For that purpose, we designed and qualified a scaled-down Good Manufacturing Practices (GMP) production method, able to produce small batches (1-4 mg) of plasmid. The developed method does not require any complex production equipment and utilizes only disposable production materials, which makes it easy to implement and simplifies line-clearance. We have successfully used this method to produce several small batches of two different plasmids. The produced plasmids, both formulated in an Electroporation Buffer, are mixed and filled into small, single-use, aliquots. Quality control confirmed the robustness of the developed method and a stability study showed that the final formulation is stable for at least two years. The final patient formulation will be subsequently used in a phase I/II clinical trial in which retina cells of patients with Age Related Macular Degeneration, are transfected. The presented production method can be generically used for other plasmid constructs and final formulation designs.
在过去几年中,对小批量临床级质粒DNA的需求一直在增长。为此,我们设计并验证了一种缩小规模的良好生产规范(GMP)生产方法,能够生产小批量(1-4毫克)的质粒。所开发的方法不需要任何复杂的生产设备,仅使用一次性生产材料,这使得它易于实施并简化了清场工作。我们已成功使用此方法生产了几小批两种不同的质粒。所生产的质粒均配制在电穿孔缓冲液中,混合后装入小的一次性等分试样中。质量控制证实了所开发方法的稳健性,稳定性研究表明最终制剂至少两年内稳定。最终的患者制剂随后将用于一项I/II期临床试验,在该试验中对年龄相关性黄斑变性患者的视网膜细胞进行转染。所展示的生产方法可广泛用于其他质粒构建体和最终制剂设计。